The present invention is directed to carbocyclic hydrazino compounds that function
as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive
amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I
(VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions
and diseases including, but not limited to, a number of inflammatory conditions
and diseases (in particular chronic inflammatory conditions such as chronic arthritis,
inflammatory bowel diseases, and chronic skin dermatoses), diseases related to
carbohydrate metabolism and to aberrations in adipocyte differentiation or function
and smooth muscle cell function, and vascular diseases. The novel compounds have
the general formula:
##STR1##
or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R1
to R11 are as defined herein.
